Vijay Tammara has sold OCGN and made no open-market buys since May 2021

Tammara Vijay (more commonly referenced publicly as Dr. Vijay Tammara) is a senior regulatory and development executive in the biopharmaceutical industry and a corporate insider at Ocugen, Inc.( At Ocugen, he has served as Senior Vice President, Regulatory and Quality under an amended and restated executive employment agreement effective January 1, 2020, reflecting his role as a key member of the company’s leadership team and an SEC-reportable insider.( In 2025, Ocugen announced his appointment to the newly created position of Chief Development Officer, leveraging more than 32 years of global regulatory experience as the company advances its gene therapy programs for blindness diseases.(

Dr. Tammara’s career spans senior roles at major life sciences organizations and the U.S. Food & Drug Administration, with contributions to at least nine marketing authorizations including Biologics License Applications and New Drug Applications across global markets.( Before joining Ocugen, he held regulatory leadership and advisory positions at Sanofi, Wyeth/Pfizer, Merck, and other firms, as well as at the FDA in clinical pharmacology.( He is a member of the American Association of Pharmaceutical Scientists, and his expertise covers biotechnology, biosimilars, 505(b)(2) pathways, and complex regulatory submissions.( Dr. Tammara earned his Ph.D. in Pharmaceutics and Pharmacokinetics from the University of Louisiana at Monroe, following graduate study at Nagpur University and an undergraduate degree from Kakatiya University.(

Written by Perplexity from public sources.